Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34⁺ cells
J. Clin. Invest. Laure A. Moutouh-de Parseval, et al. 118:248 doi:10.1172/JCI32322 [Go to this article.]

Figure 1
Pomalidomide and lenalidomide modulate erythroid differentiation. Expanded human CD34⁺ cells were differentiated to the erythroid lineage in the presence of increasing concentrations of pomalidomide and lenalidomide for 6 days. (A) Surface expression of erythroid markers glycophorin A (CD235a) and transferrin receptor (CD71) was monitored by flow cytometry. (B and C) CD253a⁺CD71⁺ and CD34⁺CD36⁺ cells were monitored by flow cytometry. (D and E) Apoptosis and viability of cells cultured with increasing concentration of pomalidomide and lenalidomide were measured using ViaCount. Results are representative of 3 independent experiments.